840 related articles for article (PubMed ID: 33038432)
1. Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis.
Frenette C; Kayali Z; Mena E; Mantry PS; Lucas KJ; Neff G; Rodriguez M; Thuluvath PJ; Weinberg E; Bhandari BR; Robinson J; Wedick N; Chan JL; Hagerty DT; Kowdley KV;
J Hepatol; 2021 Feb; 74(2):274-282. PubMed ID: 33038432
[TBL] [Abstract][Full Text] [Related]
2. Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension.
Garcia-Tsao G; Bosch J; Kayali Z; Harrison SA; Abdelmalek MF; Lawitz E; Satapathy SK; Ghabril M; Shiffman ML; Younes ZH; Thuluvath PJ; Berzigotti A; Albillos A; Robinson JM; Hagerty DT; Chan JL; Sanyal AJ;
J Hepatol; 2020 May; 72(5):885-895. PubMed ID: 31870950
[TBL] [Abstract][Full Text] [Related]
3. Emricasan Improves Liver Function in Patients With Cirrhosis and High Model for End-Stage Liver Disease Scores Compared With Placebo.
Frenette CT; Morelli G; Shiffman ML; Frederick RT; Rubin RA; Fallon MB; Cheng JT; Cave M; Khaderi SA; Massoud O; Pyrsopoulos N; Park JS; Robinson JM; Yamashita M; Spada AP; Chan JL; Hagerty DT
Clin Gastroenterol Hepatol; 2019 Mar; 17(4):774-783.e4. PubMed ID: 29913280
[TBL] [Abstract][Full Text] [Related]
4. A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis.
Harrison SA; Goodman Z; Jabbar A; Vemulapalli R; Younes ZH; Freilich B; Sheikh MY; Schattenberg JM; Kayali Z; Zivony A; Sheikh A; Garcia-Samaniego J; Satapathy SK; Therapondos G; Mena E; Schuppan D; Robinson J; Chan JL; Hagerty DT; Sanyal AJ
J Hepatol; 2020 May; 72(5):816-827. PubMed ID: 31887369
[TBL] [Abstract][Full Text] [Related]
5. Risk of further decompensation/mortality in patients with cirrhosis and ascites as the first single decompensation event.
Balcar L; Tonon M; Semmler G; Calvino V; Hartl L; Incicco S; Jachs M; Bauer D; Hofer BS; Gambino CG; Accetta A; Brocca A; Trauner M; Mandorfer M; Piano S; Reiberger T;
JHEP Rep; 2022 Aug; 4(8):100513. PubMed ID: 35845294
[TBL] [Abstract][Full Text] [Related]
6. Beta-blockers or Placebo for Primary Prophylaxis (BOPPP) of oesophageal varices: study protocol for a randomised controlled trial.
Patel VC; McPhail MJ; Uddin R; Jafari H; Lawrence V; Le Boutillier C; Shearer J; Yaziji N; Cape A; Ahmed H; Ward C; Walsh P; Besly K; Zamalloa A; Kelly J; ; Carter B
Trials; 2024 Apr; 25(1):265. PubMed ID: 38627804
[TBL] [Abstract][Full Text] [Related]
7. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis.
Ripoll C; Groszmann R; Garcia-Tsao G; Grace N; Burroughs A; Planas R; Escorsell A; Garcia-Pagan JC; Makuch R; Patch D; Matloff DS; Bosch J;
Gastroenterology; 2007 Aug; 133(2):481-8. PubMed ID: 17681169
[TBL] [Abstract][Full Text] [Related]
8. Hip Fractures in Patients With Liver Cirrhosis: Worsening Liver Function Is Associated with Increased Mortality.
Hundersmarck D; Groot OQ; Schuijt HJ; Hietbrink F; Leenen LPH; Heng M
Clin Orthop Relat Res; 2022 Jun; 480(6):1077-1088. PubMed ID: 34978539
[TBL] [Abstract][Full Text] [Related]
9. Current and future pharmacological therapies for managing cirrhosis and its complications.
Kockerling D; Nathwani R; Forlano R; Manousou P; Mullish BH; Dhar A
World J Gastroenterol; 2019 Feb; 25(8):888-908. PubMed ID: 30833797
[TBL] [Abstract][Full Text] [Related]
10. Acute Liver Injury and Decompensated Cirrhosis.
Crismale JF; Friedman SL
Med Clin North Am; 2020 Jul; 104(4):647-662. PubMed ID: 32505258
[TBL] [Abstract][Full Text] [Related]
11. [The effect of portal hypertension on prognosis in patients with decompensated liver cirrhosis].
Zhang JY; Kuai JH; Jia JD; Wang BE; Qin CY
Zhonghua Gan Zang Bing Za Zhi; 2009 Apr; 17(4):263-5. PubMed ID: 19403023
[TBL] [Abstract][Full Text] [Related]
12. Randomised clinical trial: emricasan versus placebo significantly decreases ALT and caspase 3/7 activation in subjects with non-alcoholic fatty liver disease.
Shiffman M; Freilich B; Vuppalanchi R; Watt K; Chan JL; Spada A; Hagerty DT; Schiff E
Aliment Pharmacol Ther; 2019 Jan; 49(1):64-73. PubMed ID: 30430605
[TBL] [Abstract][Full Text] [Related]
13. Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis.
Vlachogiannakos J; Viazis N; Vasianopoulou P; Vafiadis I; Karamanolis DG; Ladas SD
J Gastroenterol Hepatol; 2013 Mar; 28(3):450-5. PubMed ID: 23216382
[TBL] [Abstract][Full Text] [Related]
14. A Placebo-Controlled, Multicenter, Double-Blind, Phase 2 Randomized Trial of the Pan-Caspase Inhibitor Emricasan in Patients with Acutely Decompensated Cirrhosis.
Mehta G; Rousell S; Burgess G; Morris M; Wright G; McPherson S; Frenette C; Cave M; Hagerty DT; Spada A; Jalan R
J Clin Exp Hepatol; 2018 Sep; 8(3):224-234. PubMed ID: 30302038
[TBL] [Abstract][Full Text] [Related]
15. Gut metagenome-derived signature predicts hepatic decompensation and mortality in NAFLD-related cirrhosis.
Sharpton SR; Oh TG; Madamba E; Wang C; Yu RT; Atkins AR; Huan T; Downes M; Evans RM; Loomba R
Aliment Pharmacol Ther; 2022 Nov; 56(10):1475-1485. PubMed ID: 36164267
[TBL] [Abstract][Full Text] [Related]
16. Glucagon-Like Peptide-1 Receptor Agonists and Hepatic Decompensation Events in Patients With Cirrhosis and Diabetes.
Simon TG; Patorno E; Schneeweiss S
Clin Gastroenterol Hepatol; 2022 Jun; 20(6):1382-1393.e19. PubMed ID: 34256144
[TBL] [Abstract][Full Text] [Related]
17. Diagnosis and Management of Cirrhosis and Its Complications: A Review.
Tapper EB; Parikh ND
JAMA; 2023 May; 329(18):1589-1602. PubMed ID: 37159031
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive evaluation of effects and safety of statin on the progression of liver cirrhosis: a systematic review and meta-analysis.
Gu Y; Yang X; Liang H; Li D
BMC Gastroenterol; 2019 Dec; 19(1):231. PubMed ID: 31888534
[TBL] [Abstract][Full Text] [Related]
19. Poor Outcomes of Cirrhosis due to Nonalcoholic Steatohepatitis Compared With Hepatitis B After Decompensation With Ascites.
Tan HK; Teng MLP; Soh AYS; Cheo SHY; Fook-Chong S; Goh GBB; Tan CK; Wong GW; Lee GH; Chang JPE
Am J Gastroenterol; 2021 Jul; 116(7):1437-1446. PubMed ID: 33834737
[TBL] [Abstract][Full Text] [Related]
20. Presentation and complications associated with cirrhosis of the liver.
Poordad FF
Curr Med Res Opin; 2015 May; 31(5):925-37. PubMed ID: 25697811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
